Silver Ring Value Partners: Jazz Pharmaceuticals (JAZZ) Is a “High Uncertainty With Low Risk” Investment [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
A copy of the letter can be downloaded here . The strategy returned -9.2% (net) in the last 12 months compared to a 35.2% return for the Russell 3000 Index and a 33.1% return for the MSCI World Index during the same period. The portfolio is more undervalued and better balanced than a year ago, and the firm believes it will benefit them working toward the long-term objective of safely compounding capital. In addition, please check the fund's top five holdings to know its best picks in 2024. Silver Ring Value Partners highlighted stocks like Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) in the third quarter 2023 investor letter. Headquartered in Dublin, Ireland, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a biopharmaceutical company. The one-month return of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was 3.97%, and its shares lost 0.57% of their value over the last 52 weeks. On November 18, 2024, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stock closed at $117.59 per share with a market capitalization
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.MarketBeat
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $163.00 price target on the stock, down previously from $166.00.MarketBeat
- FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) [Yahoo! Finance]Yahoo! Finance
JAZZ
Earnings
- 11/6/24 - Beat
JAZZ
Sec Filings
- 11/21/24 - Form 8-K
- 11/13/24 - Form 4
- 11/12/24 - Form SC
- JAZZ's page on the SEC website